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1738In December 2013, we performed our 1000th ventricular assist device implantation at the Texas Heart Institute.
In my professional career, I have been fortunate to see the development of numerous mechanical circulatory
support devices for the treatment of patients with advanced heart failure. In fact, most of the cardiac pumps
in wide use today were developed in the Texas Heart Institute research laboratories in cooperation with the
National Heart, Lung and Blood Institute or device innovators and manufacturers and implanted clinically at
our partner St. Luke’s Episcopal Hospital. My early involvement in this field was guided by my mentors,
Dr Michael E. DeBakey and, especially, Dr Denton A. Cooley. Also, many of the advances are directly
attributable to my ongoing clinical experience. What I learned daily in my surgical practice allowed me to
bring insights to the development of this technology that a laboratory researcher alone might not have had.
Young academic surgeons interested in this field might bewell served to be active not only in laboratory research
but also in clinical practice. (J Thorac Cardiovasc Surg 2014;147:1738-44)I first became involved in the field of mechanical circulatory
support in 1965 as a student at Baylor University Medical
School. The previous year, Dr Michael DeBakey had been
awarded the first federal grant for establishing a program
at Baylor to develop a total artificial heart (TAH). For my
second-year research project, I worked with Dr Domingo
Liotta, under DeBakey’s supervision, to develop and test
the TAH. At that time, Dr Denton Cooley was on the
faculty at Baylor, and he was also interested in artificial
devices.
As a senior medical student at Baylor, I had an experience
that further focused my interest on artificial hearts.
I scrubbed in for an aortic valve replacement in a young
Italian boy whose case I had worked up earlier. He seemed
to be doing well after the operation. But the night of the
surgery, his heart fibrillated. We opened his chest in the
recovery room, and I began massaging his heart. As long
as I massaged his heart, he was alive. awake. looking
at me. But despite our efforts, he died. It occurred to me
then that if my hand could keep this young boy alive, why
couldn’t we make a pump that would keep him alive?
The next year, in 1969, Dr Denton Cooley implanted a
TAH in a human for the first time, with the assistance of
Dr Liotta.1 Because that operation resulted in considerable
controversy, Cooley and Liotta resigned from Baylor, ande Center for Cardiac Support, Texas Heart Institute, Houston, Tex; and Baylor
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The Journal of Thoracic and Cardiovascular Surthe device program there was discontinued. Dr DeBakey
did not to speak to Cooley for the next 38 years. Dr Cooley
started his own device program at the Texas Heart Institute
(THI), which he had founded in 1962. Although Cooley had
the world’s largest heart transplant program, his outcomes
and those of others were poor, so by 1971, he and most other
surgeons had stopped doing transplants. As a result,
the Devices and Technology Branch of the National
Heart and Lung Institute under the direction of John
Watson—now the National Heart, Lung and Blood Institute
(NHLBI)—changed its focus to support development of a
long-term (destination) left ventricular assist device
(LVAD). This became the main goal of THI’s Surgical
Research Laboratory, which Cooley established at THI in
1972. The laboratory was initially directed by Dr John
Norman, who had come from Boston.
I began my cardiac training at THI under Dr Cooley in
1974, after completing my general surgery residency under
Dr DeBakey. I made the decision to go to THI so that I could
continue device research. Although I thought my decision
to leave Baylor for THI would go unnoticed, Dr DeBakey
did not speak to me for another 10 years.
In 1981, when Dr Norman left THI, I was appointed
director of the research laboratory. I have now been
involved in the research and clinical development of
mechanical circulatory support for nearly half a century.ABDOMINAL LVAD
With NHLBI support, our THI laboratory worked on
developing an abdominally positioned, pulsatile-flow
LVAD. Between 1975 and 1980, 22 patients were supported
with this device, and the series included the first bridge-to-
transplant with an LVAD in 1978.2 The devicewas indicated
mainly for postcardiotomy shock, to provide support until
the heart could recover. Although the LVAD functioned
well, the delay before implantation was so long that thegery c June 2014
FIGURE 1. First patient to have an electrical XVE HeartMate implanted
and the first patient to be discharged from the hospital with an LVAD.
(Reprinted with permission from Lippincott Williams & Wilkins.)
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long-term survivors.
In our laboratory, research was also underway to develop
a destination-therapy LVAD. Our primary engineering
partner was Boston-based Thermo Cardiosystems. The
request for proposal called for a device with primary goals
of reliable 2-year durability, transcutaneous power, and
up to 12 L/min of flow. In pursuing these goals, we
encountered 2 important barriers: compliance-chamber
performance and inflow-graft occlusion. The compliance
chamber was necessary to compensate for volume
displacement behind the pump diaphragm. Despite
extensive research, we could not achieve 2-year
compliance-chamber durability. To solve this problem, I
suggested simple percutaneous venting to the atmosphere,
an idea that was based on my experience with chronic
venting of bronchopleural fistulas in tuberculosis patients.
With percutaneous venting, transcutaneous power became
unnecessary.
The other problem that nearly led to failure of our LVAD
program was inflow-graft occlusion. Possibly, Dr DeBakey
should be credited for solving this problem. When I was an
intern, he reprimanded me for asking him why a patient’s
femoral-popliteal graft kept occluding. After ‘‘frogging’’
me in the chest (a common occurrence in those days), he
said and made me repeat, ‘‘When blood stops moving, it
clots. Got that? When blood stops moving, it clots.’’ I never
forgot that incident. Because the early LVAD design
included a long inflow graft, blood stoppage occurred
during systole, a condition that led to accelerated pannus
formation and graft occlusion. I solved this problem by
simply shortening the inflow graft so that the pump was
juxtaposed to the heart, minimizing stasis and controlling
pannus.3
In 1994, this pump (the pneumatic HeartMate) became
the first implantable device to be approved by the Food
and Drug Administration (FDA) as a bridge to transplanta-
tion.4,5 Without the solution of these 2 problems, which
represented finite barriers to further pump development,
this milestone would not have been achieved.
BRIDGE TO TRANSPLANTATION
The world’s first 3 clinical bridge-to-transplant
experiences (2 TAHs and 1 LVAD) occurred at THI.6,7 All
3 patients died of septic complications. After cyclosporine
was introduced (a more forgiving immunosuppressant),
we and others had renewed interest in cardiac
transplantation. Our early transplant experience was
favorable, even in patients with active sepsis.8 This also
encouraged us to begin a new bridge-to-transplant program.
In 1986, I implanted the first HeartMate as a bridge
to transplantation. Although developed for destination
therapy, it was clearly satisfactory as a bridging device.
Our favorable initial experience with this device as a bridgeThe Journal of Thoracic and Carto transplantation is what led to its widespread use and
ultimate FDA approval.4
In 1991, I implanted the first electrically powered
HeartMate LVAD. After more than 500 days of support,
that patient became the first to be discharged from the
hospital with an LVAD (Fig 1).9 In 1999, the untethered
HeartMate XVE was selected for the REMATCH trial
(Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure).10,11 That trial, led
by Dr Eric Rose, resulted in the first FDA approval of an
LVAD for destination therapy, thus achieving the original
goal of the NHLBI request for proposal issued more than
20 years earlier.
BIOMEDICUS CENTRIFUGAL-FORCE LVAD
I became interested in a continuous-flow assist device for
ventricular support early in my professional career. I had
used the extracorporeal BioMedicus centrifugal-force
pump for both a short-term LVAD and an extracorporeal
membrane oxygenator, and this experience convinced me
that continuous flowmight also work for long-term support.
I also remembered being fascinated by an embryology
demonstration during an undergraduate biology course.
The professor showed how blood flow in the capillaries of
the chick embryo is continuous.
We continued to develop the BioMedicus pump as an
implantable pump, and in 1984, I successfully implanted
a short-term device in an acute experiment. To my
knowledge, this was the first experimental implantation ofdiovascular Surgery c Volume 147, Number 6 1739
FIGURE 2. First patient to receive a Hemopump (center), shown with
Rich Wampler (left) and me (right). (Reprinted with permission from the
Texas Heart Institute Journal.)
FIGURE 3. First patient to have a Jarvik 2000 implanted.
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the American Society for Artificial Internal Organs was
met with skepticism. At the time, we seemed to be the
only ‘‘research center’’ investigating long-term, implant-
able, nonpulsatile devices.
THE HEMOPUMP
Because of my interest in nonpulsatile flow, Dr Richard
Wampler, whom I had not known before, approached me
at a conference in 1986 with his design for a small,
axial-flow pump for temporary support of the failed
ventricle. This promising device, called the Hemopump,
spun at 25,000 rpm and was being manufactured by the
Nimbus Company (Rancho Cordova, Calif). I was
concerned that this pump might act like a Waring blender
and injure the fragile blood cells. However, in animal
experiments we began that same year, Wampler and I
confirmed its safety. In 1988, I successfully implanted the
Hemopump in a patient—the first continuous-flow LVAD
implanted (Fig 2).12,13 This experience showed that,
contrary to conventional wisdom, a high-rpm, continuous-
flow intravascular pump was well tolerated by the
circulatory system. In my opinion, this was the single
most important event in the development of continuous-
flow blood pumps. However, due to lack of funding,
manufacturing was discontinued. Nevertheless, the
Hemopump experience ultimately led to the development
of other axial-flow blood pumps.
JARVIK 2000
At the 1986 meeting where I met Rich Wampler, I was
also approached by Dr Robert Jarvik, who shared with me
his concept of a long-term, implantable, continuous-flow
LVAD. I was intrigued by his device’s potential
and suggested that it be placed directly in the left ventricle,
thus eliminating the necessity for an extracardiac1740 The Journal of Thoracic and Cardiovascular Surinflow conduit. However, because this LVAD would be
a long-term device, it would need implantable, blood-
washed bearings. At that time, research experience
indicated that bearings required lubrication, making
blood-washed bearings a barrier to the clinical application
of such a pump. And, in fact, in our initial laboratory
experiments, we encountered hemolysis and bearing
seizure. However, encouraged by the success of axial
flow in the Hemopump, we persevered, and by the late
1980s, Jarvik had constructed a device with blood-
immersed bearings that worked well in longer-term
animal experiments. This important contribution by
Dr Jarvik was vital to the success of implantable,
axial-flow blood pumps.
The first successful clinical implantation of the Jarvik
device occurred in April 2000 (Fig 3).14 We began a
destination-therapy trial in Oxford, England, 2 months later.
Dr SteveWestaby and I implanted the pump, and the patient
survived for 7.5 years (Fig 4).15
The investigative and clinical success of these 2 pumps
formed the foundation for further developments in
continuous-flow pump technology. The main obstacles to
the clinical use of these devices (blood damage from the
high-rpm pump [Hemopump] and the perceived barrier of
blood-washed bearings [Jarvik 2000]) were overcome by
the combined efforts of Wampler and Jarvik, working
with the THI laboratory and me. Because of THI’s
affiliation with St. Luke’s Episcopal Hospital in
Houston, where Dr Cooley had his clinical practice, we
had unique access to what was then the world’s largest
cardiovascular program. This allowed us to quicklygery c June 2014
FIGURE 4. First patient to receive a Jarvik 2000 LVAD for destination
therapy.
FIGURE 5. First patient to have the redesigned HeartMate II implanted.
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pumps. The importance of this partnership cannot be
underestimated.
HEARTMATE II VAD
The clinical success of the Hemopump stimulated the
Nimbus Company to begin developing another pump,
which ultimately became the HeartMate II. This device
would also be an implantable, axial-flow blood pump for
long-term use. At the time, I was the only surgeon actively
involved in implantable continuous-flow pump research, so
I consulted for both Nimbus and Jarvik Heart (New York
City, NY). John Moise, at Nimbus, was leading the team
to develop the pump but encountering difficulties with
magnetic suspension of the rotor. I asked Moise, ‘‘Why
don’t you just make a bigger Hemopump with bearings?’’
He laughed and said, ‘‘Bud, you don’t know anything about
bioengineering. You can’t have non-lubricated bearings in
the bloodstream.’’ I replied, ‘‘Rob and I don’t know that
you can’t have blood-washed bearings. In fact, a calf in
Houston has had a pump with blood-washed bearings for
8 months; that calf doesn’t seem to know either.’’ Had I
not been working with both Jarvik and Wampler and had
there not been collegiality among the researchers involved
in the early development of these devices, the future of
axial-flow blood pumps might have been different. When
Nimbus could no longer fund development, Bartley Griffith
and the University of Pittsburgh and, subsequently,
Thoratec intervened and saved the HeartMate II.
Beginning in 2001, the HeartMate II was implanted in
European patients, but early pump thrombosis occurred.
Because of my familiarity with this pump and longstanding
experience in the field, I was contacted for my opinion. TheThe Journal of Thoracic and Cardevice had been manufactured with pump stators that had
been textured with sintered titanium, a technology we
developed in the 1970s for use in the early, large pulsatile
pumps. This texture resulted in tissue proliferation on the
textured surface, which, although an asset in the pulsatile
pumps, was a liability in the narrowed blood pathway of
the nonpulsatile pumps. We recommended removing the
texturing, which solved this problem. We implanted the
redesigned pump in the first patient in November 2003
(Fig 5).16 Since then, more than 15,000 HeartMate II pumps
have been implanted worldwide, and this device remains
the most widely used implantable LVAD. (Recently,
I made a presentation in the Central Asian country of
Kazakhstan and was somewhat surprised to learn that
more than 100 of these pumps have been implanted there.)HEARTWARE LVAD
The engineering of what would become the HeartWare
LVAD began in 1994 when Dr Robert Fine, an early
supporter of blood pump technology, asked my advice for
developing the next-generation pump. I said that I believed
continuous-flow VADs were ‘‘the future’’ but that 3
improvements had to be made. First, blood-washed
bearings needed to be replaced by amagnetically suspended
rotor. At the time, I was concerned about long-term bearing
durability (in fact, patients have now livedmore than 9 years
with bearing pumps). Second, the pump needed to be a flat-
surface, centrifugal-force pump, so that it would fit on the
diaphragmatic surface of the heart and be able to function
as both a left and a right VAD. To date, this is the only device
that was designed specifically for use as a right VAD. Third,
the pump needed to fit inside the pericardial sac to eliminate
the need for a pump pocket, which contributed to andiovascular Surgery c Volume 147, Number 6 1741
FIGURE 6. First patient to receive a total heart replacement with
2 HeartMate II VADs.
FIGURE 7. The AbioCor total artificial heart, shown next to the newer
generation and much smaller totally implantable, continuous-flow Bivacor
artificial heart currently being developed in the THI laboratories.
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pler and by 2001 had completed the basic design. However,
before clinical trials could begin, the company (Kriton)
declared bankruptcy and was reformed by other investors
under the name HeartWare (HeartWare International, Inc,
Miami Lakes, Fla). The HeartWare pump was first im-
planted in European and Australian patients and is now
the second most widely used continuous-flow pump.17,18 I
am gratified that the 3 original goals I proposed more than
20 years ago have been clinically validated (particularly
as shown by the widespread use of this pump for right-
sided heart failure in Europe).
RESTING THE HEART
In my initial experience with the HeartMate, I found
that native ventricular function physiologically and
anatomically improved in hearts unloaded with this pump.
In 1992, we published a paper that showed histologic
evidence of this improvement,19 and in 1994, I presented
a paper on the results of ventricular unloading.4 The longer
durability and safety of the newer, continuous-flow VADs
now gives us an even greater opportunity to rest the heart
and potentially discontinue support and, perhaps, avoid
transplantation altogether.
TOTALLY IMPLANTABLE ARTIFICIAL HEART
In 1985, I was selected to be on the NHLBI Advisory
Council. At that time, the National Institutes of Health
were not directly involved in artificial heart research, and
I was asked to make recommendations for TAH research.
That talk was attended by 300 NHLBI faculty members,
including Dr DeBakey. Afterward, he came up to me.
I was surprised as he had not spoken to me for more than
10 years. He said, ‘‘Bud, you failed to emphasize the
importance of the blood-biomaterial interface.’’ He was
right, I had barely mentioned it, but it didn’t seem important
for a mostly lay audience. He then said, ‘‘You know,
inattention to detail is the hallmark of mediocrity’’ and
walked off. Even though his words sounded negative to
others with me, knowing him, I realized that this comment
meant I was back in his ‘‘good graces.’’ And after that, he
spoke to me every time we met.
I proposed that NHLBI develop a pump that would be
transcutaneously powered and, therefore, untethered, and
be potentially durable enough so that patients could return
to meaningful lives. This proposal resulted in the funding
of what eventually became the AbioCor TAH. In the THI
laboratory, I implanted more than 50 of these devices,
which supported calves successfully for up to 3 months,
thereby confirming feasibility.20 Further research in
collaboration with the Jewish Hospital in Louisville
resulted in the first clinical implant of this pump there in
July 2001.21 I subsequently implanted 5 of these pumps
clinically. One of the Louisville patients survived for1742 The Journal of Thoracic and Cardiovascular Surmore than 17 months. Although this technology appeared
promising, economic and administrative issues limited its
subsequent clinical use.
CONTINUOUS-FLOW TAH
My clinical experience with continuous-flow pumps
convinced me that the same technology could be utilized
to develop a long-term TAH. Compared with pulsatile
devices, a continuous-flow TAH would have a huge
advantage, as it would be inflow-sensitive and, thus, like
the native heart, automatically adjust right- and left-flow
imbalances. The first patient in whom we implanted a
HeartMate II did not have a pulse for more than a year
yet remained in New York Heart Association functional
class I. This experience indicated that a pulse was not
necessary for effective long-term cardiac support.
Encouraged by this result, in December 2005, we
successfully excised the heart in a calf and replaced itgery c June 2014
FIGURE 8. Congressional Gold Medal ceremony in 2008 honoring
Dr Michael DeBakey (middle). Among those invited by Dr DeBakey
were Dr Denton Cooley (right) and me (left). (Photograph courtesy of
the Texas Heart Institute.)
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experimental procedure to use implantable, continuous-
flow pumps for total circulatory support. Since then, we
have demonstrated in more than 30 cases that calves can
be well sustained (even walking on treadmills) for up to
90 days without pulsatile blood flow.22 This experience
led me to use this total heart replacement technology in a
55-year-old man dying of severe cardiac amyloidosis.23
Clinically, the patient did well. He awoke from his surgery
and was activementally and physically, but the amyloid was
found to involve the liver, lungs, and kidneys, so support
was electively discontinued after 5.5 weeks (Fig 6).
We are currently developing a totally implantable
continuous-flow TAH (the Bivacor) that has shown
feasibility in animal experiments, and we hope that this
pump will finally translate into a totally contained and
durable cardiac replacement device (Fig 7). It is being
further developed in the THI laboratories under the
leadership of Daniel Timms, an outstanding young
engineer. The device has only 1 moving part and no
bearings or valves, so we anticipate that it has the potential
for years of sustained use.
CONCLUSIONS
In December 2013, we performed our 1000th VAD
implantation at the THI. In my professional career, I have
been fortunate to have embarked on the challenging but
rewarding care of patients with advanced heart failure.
I began this journey during the idealistic Kennedy era,
which had the goals of going to the moon, curing hungerThe Journal of Thoracic and Carand poverty, as well as creating an artificial heart. Except
for reaching the moon, these laudable goals have remained
elusive. It is personally gratifying to see that most of the car-
diac pumps that are widely used today initially came to light
initially in the Baylor and then in the THI research
laboratories. None of these breakthroughs would have
happened without the guidance of mymentors, Dr DeBakey
and, especially, Dr Cooley (Fig 8). Also, many of the
advances were directly attributable to my ongoing clinical
experience, as I never stopped being an active surgeon
and practicing physician throughout my career. My clinical
experience was extremely important to my research
contributions, and this dual approach is likely valuable for
current, young clinical investigators.
I would like to acknowledge Marianne Mallia, ELS,
for editorial assistance in the preparation of this manuscript.References
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